Biotech startup Voronoi scraps IPO plan Startup has failed to draw enough bids for planned listing
Translated by Kim So-in 공개 2022-03-17 08:12:05
이 기사는 2022년 03월 17일 07:57 thebell 에 표출된 기사입니다.
South Korea’s biotech startup Voronoi has scrapped its plan to go public after getting lukewarm response from institutional investors in its two-day bookbuilding process.Voronoi has cancelled its initial public offering (IPO) plan as it only drew bids from some 20 institutions in its bookbuilding, according to industry sources on Tuesday. Most of the institutions decided not to make bids at the last minute.
“The company’s growth potential was high, but many of the institutions decided not to participate in the bookbuilding amid unfavorable market conditions,” an official at one asset management firm in Seoul said. “All of the asset managers I know made their final decisions to withdraw this time.”
Voronoi had to attract bids worth 100 billion won ($80 million) based on the bottom end of its price range, but the bids drawn were worth much less than that.
Voronoi was valued at 1.2 trillion won in its 100 billion won pre-IPO funding round in 2019, but had to lower its valuation following two failures in technology evaluations.
The biotech startup could have been the first unicorn going public in the country to benefit from a special exemption for listing. This allows companies to apply for preliminary review for listing on the Kosdaq if their market capitalization exceeds 500 billion won and pass technology evaluation from one independent evaluating agency instead of two. Voronoi received an A rating from Korea Technology Finance Corporation and valued itself at as high as 860 billion won in its registration statement.
Voronoi CEO Kim Dae-kwon himself conducted IR session for the firm’s successful market debut, but failed to attract positive response amid frozen investor sentiment toward biotech firms. (Reporting by Chan-mi Oh)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- [제일약품의 온코닉테라퓨틱 첫 '신약']세번째 P-CAB '자큐보' 2년만에 신약 명맥 잇는다
- 강동그룹, 디아너스CC 품는다
- [제약사 TSR 분석]제일약품, '주가·실적·배당' 3중고 열쇠 '온코닉의 신약'
- (여자)아이들 우기, 'YUQ1' 아이튠즈 앨범차트 10개국 석권
- 박셀바이오, 진행성 간세포암 타깃 'Vax-NK' 특허 출원
- 베니스 비엔날레, 30년만에 두발로 선 '곽훈'의 의미
- [대기업 프로스포츠 전술전략]'모기업발 숙제' 엔씨다이노스, 당분간 긴축 불가피
- 하이브, '민희진 없는' 어도어 경쟁력 입증할까
- SK 오너가 3세 최성환의 '승부수'
- 어느 수집가의 꿈 '이건희 컬렉션'